BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  Merck Delays Acceleron Deal Amidst Continuing Stakeholder Criticism

  The decision came after Avoro Capital Advisors, which owns a 7% stake in Acceleron, posted its objections to the deal.

  November 1, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Deals

  Acquisition Rumors Continue to Circulate Around Aurinia as GSK Denies Interest

  GlaxoSmithKline denied reports that they were interested in acquiring Canada’s Aurinia Pharmaceuticals, although some reports claim they are preparing to bid.

  November 1, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Moderna COVID-19 Vaccine Unlikely to Be Authorized for Adolescents in 2021

  The FDA informed Moderna that it would need more time to evaluate the company’s Emergency Use Authorization (EUA) submission for its COVID-19 vaccine for adolescents 12 to 17 years of age.

  November 1, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  FDA Approval of AbbVie Eye Drop a New Moment in Presbyopia Treatment

  The decision made VUITY the very first and only eye drop to be approved for the Presbyopia treatment. Follow the article to know aspects of this new treatment.

  November 1, 2021

   · 

  2 min read

   · 

  Kaylei Whalen
• 

  Drug Development

  FDA Greenlights Novartis’ First-in-Class Therapy for CML

  Scemblix is the first-in-class FDA-approved treatment for adult patients diagnosed with Philadelphia chromosome-positive chronic myeloid leukemia.

  November 1, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  BioCapital

  NIH Faces Criticism After Notice Encouraging Diverse Applications Removed

  The National Institutes of Health has removed a notice aimed at encouraging grant proposals from minority scientists from three separate institutes.

  November 1, 2021

   · 

  2 min read

   · 

  Heather McKenzie
• 

  Drug Development

  New Precision Platform Could Be Cell Therapy Game-Changer

  BlueSphere Bio aims to overcome challenges in the CAR T space with a precision approach to T cell therapy.

  November 1, 2021

   · 

  6 min read

   · 

  Heather McKenzie
• 

  Deals

  LianBio Banks $325 Million IPO to Bring New Drugs to Asian Markets

  One year after snagging $310 million in a financing round, LianBio raised $325M in its initial public offering. Its stock begins selling today on Nasdaq under the ticker symbol “LIAN.”

  November 1, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  BioMidwest

  World Hits 5 Million COVID-19 Deaths While US Sees Reprieve

  As the world marks a grim milestone of 5 million COVID-19 deaths, public health officials are keeping a close watch on a substrain of the Delta variant.

  November 1, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Teva’s Risperidone Injectable Wards Off Schizophrenia Relapse in Phase III

  Researchers found that those who took either the once-a-month or once-every-two-month doses experienced longer periods before relapsing.

  November 1, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN